Press Releases

<<  Back

  View printer-friendly version

Allergen Research Corporation Expands Management with New VP Functions

Mary Rozenman, PhD, Joins ARC as Senior Vice President, Corporate and Commercial Development, and
Mike Holfinger, PhD, Joins as Vice President, Manufacturing

SAN MATEO, Calif., April 8, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the appointments of Mary Rozenman, PhD, as Senior Vice President, Corporate and Commercial Development, and Mike Holfinger, PhD, as Vice President, Manufacturing.

Dr. Rozenman and Dr. Holfinger fill key functions as ARC prepares for its upcoming Phase 3 clinical trial of the company’s lead product, AR 101, a standardized pharmaceutical-grade peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy (CODIT™). The company recently announced the completion of an $80 million Series B financing, which will support the Phase 3 trial along with the initiation of clinical trials for treatment of egg and milk allergies.

“We are delighted that Mary and Mike have joined us to advance ARC’s mission of improving the lives of people with food allergies,” said ARC CEO Stephen Dilly, MBBS, PhD. “The expansion of our management team, the announcement of our Series B financing and, most importantly, the recent successful completion of Phase 2 for our lead product underscore the progress ARC has made in developing products to treat food allergies. We welcome Mary and Mike to the ARC leadership team.”

Dr. Rozenman joins ARC from Longitude Capital, where she was a Vice President focused on biotechnology investments and was an observer on ARC’s Board of Directors. She was previously an Associate Principal in the Healthcare and Corporate Finance practices at McKinsey & Company, where she advised senior management of leading pharmaceutical companies on a range of strategic and operational issues across marketing, sales and corporate development, and led the firm’s global Biosimilars practice. Dr. Rozenman holds a PhD in Organic Chemistry and Chemical Biology from Harvard University and a BA in Russian Literature and Biochemistry from Columbia University.

Dr. Holfinger joins ARC from Alexza Pharmaceuticals, where he was Vice President, Manufacturing and Global Supply Chain Management. He has more than two decades of experience in process development and global manufacturing of commercial products, including seven years with Affymax, where he most recently served as Vice President, Manufacturing and CMC Development, and 14 years with Pfizer, Pharmacia and Upjohn. Dr. Holfinger earned his PhD in Chemical Engineering from the University of Wisconsin-Madison and received dual BS degrees in Applied Science and Chemistry at Miami University.

About Food Allergies
Food allergies represent an urgent and growing global unmet medical need. Approximately 15 million people in the United States and 17 million people in Europe have food allergies. Moreover, the prevalence of food allergies is increasing rapidly—in the United States, 1 in 25 children suffered from a food allergy a decade ago, compared to 1 in 13 today, and a projected 1 in 5 by 2020. For people living with food allergies, certain foods can cause severe allergic reactions, including potentially life-threatening anaphylaxis. There is no cure for food allergies. Currently, food-allergic patients manage their condition by strict allergen avoidance and carrying epinephrine auto-injectors for use in case of accidental exposure. Thus, in addition to the unmet medical need, food allergies can impose a significant quality of life burden. For more information, please visit and

About Allergen Research Corporation
Allergen Research Corporation (ARC), founded in 2011, develops treatments for food allergies using characterized oral desensitization immunotherapy (CODIT™), its proprietary approach to oral immunotherapy (OIT). CODIT combines standardized, pharmaceutical-grade food allergens with controlled up-dosing protocols to desensitize patients and increase the thresholds at which they could experience allergic reactions. ARC recently completed a successful Phase 2 study of its lead product, AR 101, a standardized, pharmaceutical-grade peanut protein formulation for the treatment of peanut allergy, one of the most common food allergies. ARC is also developing CODIT for other common food allergies, including egg and milk. For more information, please visit